Isct
Membership Organizations · 11-50 Employees
View Company Info for Free
Overview
Phone Number
(604) 874-4366Website
www.isct-na2019.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Isct
Established in 1992, International Society for Cell and Gene Therapy (ISCT) is a non-profit organization and is a growing global society of clinicians, regulators, researchers, technologists and industry partners. ISCT is the global provider focused on pre-clinical and translational aspects of developing cell-based therapeutics, thereby advancing scientific research into innovative treatments for patients. ISCT offers a unique collaborative environment that addresses three key areas of translation: Academia, Regulatory and Commercialization. The organization is based in Vancouver, British Columbia.Explore more
Popular SearchesIsctSIC Code 86,862NAICS Code 81,813Show moreIsct Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Isct your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Isct had a recent Job posting/layoffs
Check if Isct has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Isct launches new products
Funding: Get notified immidiatlly once Isct has new funding data
Congratulate Masked Content for being promoted to Masked Content at Isct
Earning: See what the market has to say on Isct recently announced quarterly report
Check out if Isct is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Isct, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Isct
Find more new buyers
Compare Similar Companies to Isct
Compare insights from companies similar to Isct, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Isct is experiencing very low activity levels compared to other companies in the Organizations sector.
What does this means?
Isct is drawing exceptional interest within the Organizations industry, suggesting notable developments or strong market momentum, learn more about Isct.
Isct Tech Stack
A closer look at the technologies used by Isct
Isct News & Media
ISCT Reaffirms Position on Addressing Ethical Implications of US Expanded Access Pathway
VANCOUVER, British Columbia--(BUSINESS WIRE)--ISCT Reaffirms Position on Addressing Ethical Implications of US Expanded Access PathwayGamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, today will share preclinical data at the International Society for Cell & Gene Therapy (ISCT) 2022, being held in San Francisco, CA, May 4-7, 2022 on GDA-301 and GDA-601, two product candidates in the Company’s NAM-enabled genetically modified natural killer (NK) pipeline. “The preclinical data genAdicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies
MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced data from a preclinical evaluation of ADI-001 at the International Society for Cell and Gene Therapy (ISCT) Annual Meeting taking place in San Francisco, May 4-7, 2022. ADI-001 is currently being evaluated in an ongoing dose escalation PhaNinety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT Meeting on Advances in Cell & Gene Therapies for Lung Diseases
NEW YORK, July 18, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, presented 90-day survival outcomes from the 222-patient randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) at an invited presentation on July 17 to the International Society for Cell & Gene Therapy (ISCT) Scientific Signatures Series on Cel
Read more news
Top Membership Organizations Companies
Frequently Asked Questions Regarding Isct
Sign Up For FreeTo access detailed company insights
Established in 1992, International Society for Cell and Gene Therapy (ISCT) is a non-profit organization and is a growing global society of clinicians, regulators, researchers, technologists and industry partners. ISCT is the global provider focused on pre-clinical and translational aspects of developing cell-based therapeutics, thereby advancing s... Read More
